2mg CS0159 for Non-alcoholic Fatty Liver Disease

"The minimum age requirement for this clinical trial is 18 years old, and the maximum age limit is 75."

"According to clinicaltrials.gov, this medical trial is currently open and actively recruiting patients; the study was initially published on February 10th 2023 with edits made as recently as February 18th of the same year."

"Affirmative, the trial is actively looking for participants. The study was initially posted on February 10th 2023 and recently updated on 18th of the same month. Currently, they are searching to recruit 100 patients from 1 site."

"Our assessment of 1.4mg CS0159 was a 2 on our scale from 1 to 3, as this is in its Phase 2 trial and has some evidence for safety but not yet efficacy."

"Laboratory Corporation of America, the study sponsor, has reported that over a 12-week period they will be primarily measuring Adverse events. Additionally they will be assessing secondary metrics such as tmax (maximum plasma concentration time span), t1/2 (half-life of drug) and AUC (accumulation ratio)."

"This medical trial is looking for approximately 100 participants aged between 18 and 75 who have been diagnosed with non-alcoholic fatty liver disease (NAFLD). Furthermore, they must meet the following criteria: display symptoms of NASH., possess evidence of metabolic syndrome, unless their condition has already been confirmed by biopsy results; BMI >25 kg/m2 or higher (or alternatively 23kg/m2 if they are an Asian American); and steady use of antidiabetic medication, weight reduction treatments, or lipid modifiers over a 12 week period prior to randomization."